We speak science. It’s in our DNA.
With our biomedical research backgrounds and biotech communications experience, we translate the science and technology into the value story that matters for your stakeholders and business goals.
The DNA of communications is both science and art.
“It’s more than a website, a PowerPoint or a press release, it’s your story. It needs to inspire others, so together you can achieve something important.”
– Jessica Yingling, Ph.D., President of Little Dog Communications
Biotech and healthcare communications have an added layer of complexity due to the science. Jessica merges a biomedical research background with communications EQ to find the best way to convey new science and technologies to motivate audiences and stakeholders.
Before founding Little Dog Communications in 2011, Jessica was director of corporate communications at Fate Therapeutics, where she built and successfully executed a complete corporate communications program that established Fate as a pioneering company in stem cell medicines. This program led to numerous company awards and recognitions, including being named one of the most innovative biotechs by Fast Company.
Previous to Fate, Jessica was at Porter Novelli Life Sciences, where she gained experience working with a wide range of accounts from start-up biotechs translating early stage technology to public life sciences companies with marketed products.
Jessica achieved her Ph.D. in biomedical sciences from University of California, San Diego, where she was awarded a National Science Foundation pre-doctoral fellowship. She is author in multiple top-tier review articles and research papers, including Cell. She earned a B.S. with honors in biochemistry and art history from the University of Arizona, where she received a number of academic and research scholarships and awards.